\-\ Texto\\:\\ \ \(0\)\
\-\ lab\\ work\\ for\\ the\\ patient\\ was\\ unremarkable\\ to\\ include\\ negative\\ hiv\\ and\\ lyme\\ antibody\\.\\ \\ on\\ physical\\ exam\\ the\\ patient\\ complained\\ of\\ headache\\.\\ \\ he\\ was\\ mildly\\ disoriented\\ and\\ ataxic\\.\ \(0\)\
\-\ patient\\ was\\ treated\\ with\\ high\\-dose\\ steroids\\.\\ \\ the\\ patient\\ demonstrated\\ gradual\\ improvement\\ in\\ symptoms\\ 2\\-weeks\\ following\\ initial\\ presentation\\.\ \(0\)\
\-\ image\\ findings\\ demonstrate\\ bilateral\\,\\ symmetric\\ abnormal\\ increased\\ t2\\ signal\\ within\\ the\\ white\\ matter\\ of\\ the\\ superior\\ cerebellum\\.\\ \\ there\\ is\\ mild\\ enhancement\\ of\\ the\\ affected\\ white\\ matter\\.\\ \\ there\\ is\\ no\\ mass\\ effect\\,\\ hemorrhage\\ or\\ other\\ lesions\\ within\\ the\\ brain\\ parenchyma\\.\\ \\ diffusion\\ weighted\\ images\\ are\\ negative\\ for\\ acute\\ infarct\\.\\ \\ gradient\\ echo\\ images\\ demonstrate\\ no\\ evidence\\ of\\ old\\ hemorrhage\ \(0\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ sarcoid\ \(163\)\
\-\ 26\\-year\\ old\\ active\\ duty\\ male\\ presented\\ with\\ acute\\ onset\\ of\\ ataxia\\,\\ dysarthria\\,\\ headache\\,\\ and\\ lethargy\\.\ \(1\)\
\-\ this\\ patient\\ is\\ a\\ 26\\-year\\ old\\ active\\ duty\\ male\\ who\\ presented\\ with\\ acute\\ onset\\ of\\ ataxia\\,\\ dysarthria\\,\\ headaches\\,\\ and\\ lethargy\\.\\ \\ significant\\ past\\ medical\\ history\\ included\\ vaccination\\ against\\ smallpox\\,\\ measles\\ and\\ tetanus\\ 6\\-days\\ prior\\ to\\ his\\ presentation\\.\\ \\ \\ patient\\ was\\ treated\\ supportively\\ as\\ well\\ as\\ with\\ high\\-dose\\ steroids\\.\\ \\ 2\\-weeks\\ following\\ initial\\ presentation\\,\\ the\\ patient\\â\\€\\™s\\ symptoms\\ are\\ slowly\\ improving\\ with\\ only\\ mild\\ dysarthria\\ remaining\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ dysarthria\\:\\ 0\\.08384641508590095\ \(0\)\
\-\ 2\\-weeks\\:\\ 0\\.08316526815062734\ \(0\)\
\-\ 26\\-year\\:\\ 0\\.0728010012763999\ \(0\)\
\-\ high\\-dose\\:\\ 0\\.06480762523501117\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.05400449028875644\ \(0\)\
\-\ lethargy\\:\\ 0\\.050769162447937284\ \(0\)\
\-\ acute\\:\\ 0\\.04976130493175697\ \(0\)\
\-\ disseminated\\:\\ 0\\.049100004823795035\ \(0\)\
\-\ ataxia\\:\\ 0\\.04308512435770886\ \(0\)\
\-\ duty\\:\\ 0\\.0420642414837444\ \(0\)\
\-\ presentation\\:\\ 0\\.04165189577110022\ \(0\)\
\-\ 6\\-days\\:\\ 0\\.04158263407531367\ \(0\)\
\-\ smallpox\\:\\ 0\\.038313071902861096\ \(0\)\
\-\ supportively\\:\\ 0\\.038313071902861096\ \(0\)\
\-\ steroids\\:\\ 0\\.03792196111669582\ \(0\)\
\-\ tetanus\\:\\ 0\\.03313093846574737\ \(0\)\
\-\ measles\\:\\ 0\\.032403812617505585\ \(0\)\
\-\ matter\\:\\ 0\\.031740377079252806\ \(0\)\
\-\ ataxic\\:\\ 0\\.031218367201086217\ \(0\)\
\-\ vaccination\\:\\ 0\\.031218367201086217\ \(0\)\
\-\ active\\:\\ 0\\.030778856972121512\ \(0\)\
\-\ disoriented\\:\\ 0\\.02850438538550338\ \(0\)\
\-\ patient\\:\\ 0\\.028283695832144885\ \(0\)\
\-\ headache\\:\\ 0\\.02768854186382828\ \(0\)\
\-\ improving\\:\\ 0\\.02700224514437822\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.026832609284679582\ \(0\)\
\-\ antibody\\:\\ 0\\.026792567019044096\ \(0\)\
\-\ white\\:\\ 0\\.026736832195396392\ \(0\)\
\-\ initial\\:\\ 0\\.026713039087540642\ \(0\)\
\-\ gradual\\:\\ 0\\.025864688272600442\ \(0\)\
\-\ onset\\:\\ 0\\.02544737005589764\ \(0\)\
\-\ lyme\\:\\ 0\\.024948858015803474\ \(0\)\
\-\ gradient\\:\\ 0\\.024424208793585436\ \(0\)\
\-\ treated\\:\\ 0\\.024130668264942066\ \(0\)\
\-\ negative\\:\\ 0\\.02407660529598938\ \(0\)\
\-\ following\\:\\ 0\\.022879978838690078\ \(0\)\
\-\ against\\:\\ 0\\.02259512610014787\ \(0\)\
\-\ hiv\\:\\ 0\\.022348966887079144\ \(0\)\
\-\ presented\\:\\ 0\\.021975072028513294\ \(0\)\
\-\ slowly\\:\\ 0\\.02189212808523991\ \(0\)\
\-\ complained\\:\\ 0\\.021280440239444944\ \(0\)\
\-\ mild\\:\\ 0\\.02122880616916167\ \(0\)\
\-\ echo\\:\\ 0\\.02097203099763904\ \(0\)\
\-\ remaining\\:\\ 0\\.02097203099763904\ \(0\)\
\-\ sarcoid\\:\\ 0\\.020682554835486717\ \(0\)\
\-\ symptoms\\:\\ 0\\.020091108272623955\ \(0\)\
\-\ cerebellum\\:\\ 0\\.020052689775937084\ \(0\)\
\-\ lab\\:\\ 0\\.01972070488555124\ \(0\)\
\-\ work\\:\\ 0\\.018883651266953207\ \(0\)\
\-\ improvement\\:\\ 0\\.018807569276717912\ \(0\)\
\-\ was\\:\\ 0\\.018646745702145032\ \(0\)\
\-\ included\\:\\ 0\\.018586420286628994\ \(0\)\
\-\ demonstrate\\:\\ 0\\.018551435295594724\ \(0\)\
\-\ symmetric\\:\\ 0\\.01840973367089833\ \(0\)\
\-\ diffusion\\:\\ 0\\.01804285772258378\ \(0\)\
\-\ infarct\\:\\ 0\\.01788508444868029\ \(0\)\
\-\ weighted\\:\\ 0\\.01752666035916179\ \(0\)\
\-\ affected\\:\\ 0\\.017441153828064826\ \(0\)\
\-\ mildly\\:\\ 0\\.01716683344996542\ \(0\)\
\-\ parenchyma\\:\\ 0\\.01716683344996542\ \(0\)\
\-\ images\\:\\ 0\\.015464753697635416\ \(0\)\
\-\ headaches\\:\\ 0\\.015407746882411689\ \(0\)\
\-\ within\\:\\ 0\\.015378598192321524\ \(0\)\
\-\ male\\:\\ 0\\.014577410734787482\ \(0\)\
\-\ sclerosis\\:\\ 0\\.01447790204446389\ \(0\)\
\-\ effect\\:\\ 0\\.014271501193722853\ \(0\)\
\-\ unremarkable\\:\\ 0\\.013344652918311606\ \(0\)\
\-\ superior\\:\\ 0\\.012871432533274487\ \(0\)\
\-\ past\\:\\ 0\\.012807544678992613\ \(0\)\
\-\ \\,\\:\\ 0\\.012769342713079595\ \(0\)\
\-\ image\\:\\ 0\\.01259051493536604\ \(0\)\
\-\ medical\\:\\ 0\\.012402404717292472\ \(0\)\
\-\ old\\:\\ 0\\.012381149955597942\ \(0\)\
\-\ as\\:\\ 0\\.012194127414095545\ \(0\)\
\-\ brain\\:\\ 0\\.01212901661935265\ \(0\)\
\-\ only\\:\\ 0\\.012119866313608186\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.012047295941723848\ \(0\)\
\-\ there\\:\\ 0\\.01199731657042442\ \(0\)\
\-\ demonstrated\\:\\ 0\\.011827452747438525\ \(0\)\
\-\ his\\:\\ 0\\.011617401073806282\ \(0\)\
\-\ s\\:\\ 0\\.011560224844880127\ \(0\)\
\-\ abnormal\\:\\ 0\\.011495718114692978\ \(0\)\
\-\ t2\\:\\ 0\\.011408437588445057\ \(0\)\
\-\ include\\:\\ 0\\.011307327773727767\ \(0\)\
\-\ he\\:\\ 0\\.011246166707702922\ \(0\)\
\-\ are\\:\\ 0\\.010989376155939638\ \(0\)\
\-\ significant\\:\\ 0\\.010838901655916148\ \(0\)\
\-\ enhancement\\:\\ 0\\.010804192293033189\ \(0\)\
\-\ lesions\\:\\ 0\\.010790379746905414\ \(0\)\
\-\ signal\\:\\ 0\\.010627709105060277\ \(0\)\
\-\ evidence\\:\\ 0\\.010568125393239989\ \(0\)\
\-\ who\\:\\ 0\\.010509284948781613\ \(0\)\
\-\ prior\\:\\ 0\\.010349588548124355\ \(0\)\
\-\ physical\\:\\ 0\\.009889175799911502\ \(0\)\
\-\ increased\\:\\ 0\\.009860777272639886\ \(0\)\
\-\ bilateral\\:\\ 0\\.00978215910053983\ \(0\)\
\-\ other\\:\\ 0\\.009290747871237964\ \(0\)\
\-\ well\\:\\ 0\\.009118306381927599\ \(0\)\
\-\ exam\\:\\ 0\\.00885487707523367\ \(0\)\
\-\ findings\\:\\ 0\\.008579419508443206\ \(0\)\
\-\ multiple\\:\\ 0\\.008489650959807872\ \(0\)\
\-\ no\\:\\ 0\\.008117397648149074\ \(0\)\
\-\ is\\:\\ 0\\.007956944977142343\ \(0\)\
\-\ for\\:\\ 0\\.006878378760780331\ \(0\)\
\-\ mass\\:\\ 0\\.005605948145979077\ \(0\)\
\-\ history\\:\\ 0\\.005567049706165487\ \(0\)\
\-\ the\\:\\ 0\\.005216954139759464\ \(0\)\
\-\ or\\:\\ 0\\.004724163910206167\ \(0\)\
\-\ this\\:\\ 0\\.004533666100538364\ \(0\)\
\-\ and\\:\\ 0\\.0042454954182127\ \(0\)\
\-\ to\\:\\ 0\\.004028944419273455\ \(0\)\
\-\ on\\:\\ 0\\.003414580247006736\ \(0\)\
\-\ of\\:\\ 0\\.0032972773810751445\ \(0\)\
\-\ with\\:\\ 0\\.0027595324549502297\ \(0\)\
\-\ \\.\\:\\ 0\\.002344308987560603\ \(0\)\
\-\ in\\:\\ 0\\.0019877227836804477\ \(0\)\
\-\ a\\:\\ 0\\.0018707537821632135\ \(0\)\
